alexa When Funding For Medical Countermeasures Against Rare, But Detrimental Agents Is Cost-effective | 62904
ISSN: 2157-7560

Journal of Vaccines & Vaccination
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

15th Annual Summit on Vaccines and Immunization

Mark Lawrence Johnson
MJ Lawrence Consulting, Germany
ScientificTracks Abstracts: J Vaccines Vaccin
DOI: 10.4172/2157-7560.C1.054
Abstract
Some chemical, biological, radiological, and nuclear (CBRN) agents can be very damaging and pose high risk to national security because they bear potential to induce economic and social disruption. Assuming efficacious medical research and development (R&D) is executed; populations could be protected against such CBRN agents via new prophylactic drugs and vaccines or postexposure treatment with antidotes and antimicrobials. However, the development of medical countermeasures (MedCM) against these agents is very limited. This presentation depicts specific features of the MedCM market and R&D against CBRN agents and explores the latest Ebola outbreak as an illustration of these concerns. While their R&D process and related costs are quite similar to those of commercially viable conventional diseases, it is shown that free market rewards and incentives are more uncertain and most often not sufficient for developers of MedCM to independently invest on its own since widespread dissemination of CBRN agents remains a rare and unpredictable event (e.g. few customers, low and volatile market sales potential). This results in market failures for appropriate medicines or vaccines except in the case of effective public intervention. However, priorities should be identified given the extent of such risks and the amounts of investment involved. The Ebola example is used as a case study of causal factors which led to a lack of a vaccine prior to the 2014 outbreak. In addition, possible reasons which may have triggered a re-evaluation of its prioritization as a threat worthy of high actionable concern are probed.
Biography

Mark Lawrence Johnson is one of the early pioneers to develop policy and procurement in the European biodefense market for medical countermeasures (MedCM). He has accrued a mature and extensive network. His professional credibility was born over 20 years ago when he began to represent leading global pharmaceutical companies such as Merck & Co., Eli Lilly, and Astellas. Following response to the European Commission’s (EC) Green Paper on CBRN preparedness in 2007, his participation at EC CBRN taskforce meetings was instrumental in getting fundamental economic elements adopted in its corresponding recommendations and action plan. He holds an MBA from Wake Forest University and a BA in Business Management from the University of Maryland. He is currently a Doctoral candidate at the Paris 2 University, Panthéon-Assas (LEMMA) working to determine economic mechanisms for achieving international availability of CBRN MedCM.

Email: [email protected]

image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7